Risperidone monotherapy for post-traumatic stress disorder related to sexual assault and domestic abuse in women

Prasad R. Padala, James Madison, Melanie Monnahan, William Marcil, Paul Price, Sriram Ramaswamy, Amad U. Din, Daniel R. Wilson, Frederick Petty

Research output: Contribution to journalArticle

74 Citations (Scopus)

Abstract

Post-traumatic stress disorder is a common, chronic, and often disabling mental illness. Selective serotonin reuptake inhibitors are the usual first-line treatment for post-traumatic stress disorder, but many patients fail to respond adequately. Thus, other treatment options, including the atypical antipsychotics such as risperidone, need to be tested. Women between the ages of 19 and 64 years with post-traumatic stress disorder were enrolled. Symptom severity was rated at baseline using the Treatment Outcomes Post-traumatic Stress Disorder Scale-8, Hamilton Rating Scale for Anxiety, Hamilton Rating Scale for Depression, and Clinician Administered Post-traumatic Stress Disorder Scale. After washout from other psychotropic medications, 20 participants were randomized to either risperidone or placebo. Total score on the Treatment Outcomes Post-traumatic Stress Disorder Scale-8 served as the primary outcome measure. Repeated-measures analysis of variance was followed by Newman-Keuls tests. A significant main effect exists for visits using the Treatment Outcomes Post-traumatic Stress Disorder Scale-8 raw score. For the treatment group, the difference between baseline Treatment Outcomes Post-traumatic Stress Disorder Scale-8 scores and treatment visit scores was significant beginning at visit 6 and continued through visit 11. No significant difference observed between baseline and any treatment visit for the placebo group. The Clinician Administered Post-traumatic Stress Disorder Scale, Hamilton Rating Scale for Anxiety, and Hamilton Rating Scale for Depression data revealed a similar pattern. In this small pilot study, risperidone monotherapy was more effective than placebo in the treatment of post-traumatic stress disorder.

Original languageEnglish
Pages (from-to)275-280
Number of pages6
JournalInternational Clinical Psychopharmacology
Volume21
Issue number5
DOIs
StatePublished - Sep 2006

Fingerprint

Risperidone
Post-Traumatic Stress Disorders
Placebos
Therapeutics
Anxiety
Depression
Serotonin Uptake Inhibitors
Antipsychotic Agents
Analysis of Variance
Outcome Assessment (Health Care)

All Science Journal Classification (ASJC) codes

  • Psychiatry and Mental health
  • Pharmacology (medical)
  • Neuroscience(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Risperidone monotherapy for post-traumatic stress disorder related to sexual assault and domestic abuse in women. / Padala, Prasad R.; Madison, James; Monnahan, Melanie; Marcil, William; Price, Paul; Ramaswamy, Sriram; Din, Amad U.; Wilson, Daniel R.; Petty, Frederick.

In: International Clinical Psychopharmacology, Vol. 21, No. 5, 09.2006, p. 275-280.

Research output: Contribution to journalArticle

Padala, Prasad R. ; Madison, James ; Monnahan, Melanie ; Marcil, William ; Price, Paul ; Ramaswamy, Sriram ; Din, Amad U. ; Wilson, Daniel R. ; Petty, Frederick. / Risperidone monotherapy for post-traumatic stress disorder related to sexual assault and domestic abuse in women. In: International Clinical Psychopharmacology. 2006 ; Vol. 21, No. 5. pp. 275-280.
@article{845e5ea8adca4189bbe79c53ed92ef80,
title = "Risperidone monotherapy for post-traumatic stress disorder related to sexual assault and domestic abuse in women",
abstract = "Post-traumatic stress disorder is a common, chronic, and often disabling mental illness. Selective serotonin reuptake inhibitors are the usual first-line treatment for post-traumatic stress disorder, but many patients fail to respond adequately. Thus, other treatment options, including the atypical antipsychotics such as risperidone, need to be tested. Women between the ages of 19 and 64 years with post-traumatic stress disorder were enrolled. Symptom severity was rated at baseline using the Treatment Outcomes Post-traumatic Stress Disorder Scale-8, Hamilton Rating Scale for Anxiety, Hamilton Rating Scale for Depression, and Clinician Administered Post-traumatic Stress Disorder Scale. After washout from other psychotropic medications, 20 participants were randomized to either risperidone or placebo. Total score on the Treatment Outcomes Post-traumatic Stress Disorder Scale-8 served as the primary outcome measure. Repeated-measures analysis of variance was followed by Newman-Keuls tests. A significant main effect exists for visits using the Treatment Outcomes Post-traumatic Stress Disorder Scale-8 raw score. For the treatment group, the difference between baseline Treatment Outcomes Post-traumatic Stress Disorder Scale-8 scores and treatment visit scores was significant beginning at visit 6 and continued through visit 11. No significant difference observed between baseline and any treatment visit for the placebo group. The Clinician Administered Post-traumatic Stress Disorder Scale, Hamilton Rating Scale for Anxiety, and Hamilton Rating Scale for Depression data revealed a similar pattern. In this small pilot study, risperidone monotherapy was more effective than placebo in the treatment of post-traumatic stress disorder.",
author = "Padala, {Prasad R.} and James Madison and Melanie Monnahan and William Marcil and Paul Price and Sriram Ramaswamy and Din, {Amad U.} and Wilson, {Daniel R.} and Frederick Petty",
year = "2006",
month = "9",
doi = "10.1097/00004850-200609000-00005",
language = "English",
volume = "21",
pages = "275--280",
journal = "International Clinical Psychopharmacology",
issn = "0268-1315",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Risperidone monotherapy for post-traumatic stress disorder related to sexual assault and domestic abuse in women

AU - Padala, Prasad R.

AU - Madison, James

AU - Monnahan, Melanie

AU - Marcil, William

AU - Price, Paul

AU - Ramaswamy, Sriram

AU - Din, Amad U.

AU - Wilson, Daniel R.

AU - Petty, Frederick

PY - 2006/9

Y1 - 2006/9

N2 - Post-traumatic stress disorder is a common, chronic, and often disabling mental illness. Selective serotonin reuptake inhibitors are the usual first-line treatment for post-traumatic stress disorder, but many patients fail to respond adequately. Thus, other treatment options, including the atypical antipsychotics such as risperidone, need to be tested. Women between the ages of 19 and 64 years with post-traumatic stress disorder were enrolled. Symptom severity was rated at baseline using the Treatment Outcomes Post-traumatic Stress Disorder Scale-8, Hamilton Rating Scale for Anxiety, Hamilton Rating Scale for Depression, and Clinician Administered Post-traumatic Stress Disorder Scale. After washout from other psychotropic medications, 20 participants were randomized to either risperidone or placebo. Total score on the Treatment Outcomes Post-traumatic Stress Disorder Scale-8 served as the primary outcome measure. Repeated-measures analysis of variance was followed by Newman-Keuls tests. A significant main effect exists for visits using the Treatment Outcomes Post-traumatic Stress Disorder Scale-8 raw score. For the treatment group, the difference between baseline Treatment Outcomes Post-traumatic Stress Disorder Scale-8 scores and treatment visit scores was significant beginning at visit 6 and continued through visit 11. No significant difference observed between baseline and any treatment visit for the placebo group. The Clinician Administered Post-traumatic Stress Disorder Scale, Hamilton Rating Scale for Anxiety, and Hamilton Rating Scale for Depression data revealed a similar pattern. In this small pilot study, risperidone monotherapy was more effective than placebo in the treatment of post-traumatic stress disorder.

AB - Post-traumatic stress disorder is a common, chronic, and often disabling mental illness. Selective serotonin reuptake inhibitors are the usual first-line treatment for post-traumatic stress disorder, but many patients fail to respond adequately. Thus, other treatment options, including the atypical antipsychotics such as risperidone, need to be tested. Women between the ages of 19 and 64 years with post-traumatic stress disorder were enrolled. Symptom severity was rated at baseline using the Treatment Outcomes Post-traumatic Stress Disorder Scale-8, Hamilton Rating Scale for Anxiety, Hamilton Rating Scale for Depression, and Clinician Administered Post-traumatic Stress Disorder Scale. After washout from other psychotropic medications, 20 participants were randomized to either risperidone or placebo. Total score on the Treatment Outcomes Post-traumatic Stress Disorder Scale-8 served as the primary outcome measure. Repeated-measures analysis of variance was followed by Newman-Keuls tests. A significant main effect exists for visits using the Treatment Outcomes Post-traumatic Stress Disorder Scale-8 raw score. For the treatment group, the difference between baseline Treatment Outcomes Post-traumatic Stress Disorder Scale-8 scores and treatment visit scores was significant beginning at visit 6 and continued through visit 11. No significant difference observed between baseline and any treatment visit for the placebo group. The Clinician Administered Post-traumatic Stress Disorder Scale, Hamilton Rating Scale for Anxiety, and Hamilton Rating Scale for Depression data revealed a similar pattern. In this small pilot study, risperidone monotherapy was more effective than placebo in the treatment of post-traumatic stress disorder.

UR - http://www.scopus.com/inward/record.url?scp=33746686967&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746686967&partnerID=8YFLogxK

U2 - 10.1097/00004850-200609000-00005

DO - 10.1097/00004850-200609000-00005

M3 - Article

VL - 21

SP - 275

EP - 280

JO - International Clinical Psychopharmacology

JF - International Clinical Psychopharmacology

SN - 0268-1315

IS - 5

ER -